1. Big Bristol-Myers Shareholder Opposes Celgene Deal

    Big Bristol-Myers Shareholder Opposes Celgene Deal

    One of Bristol-Myers Squibb Co.’s largest shareholders is opposing the company’s $74 billion deal to buy rival Celgene Corp., becoming the latest investor to express its unhappiness with the transaction...

    Read Full Article

    Login to comment.

  1. Categories

    1. BoardProspects Features:

      Board Recruitment Publication, BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, Competitor Corner, In the News, Member Report, Partner Publications, Question of The Week, Sponsored Content

    1. While Wellington agrees that Bristol-Myers should be active in business development that secures differentiated science and broadens the future revenue base, Wellington does not believe that the Celgene transaction is an attractive path towards accomplishing this goal.
    2. We believe that we are acquiring Celgene at an attractive price, and that this transaction presents an important and unique opportunity to create sustainable value.
  3. Topics Mentioned

  4. Authors